For example, SNORA42 has been shown to promote ESCC development by activating the DHX9/p65 axis,[18] and SNORD12B activates the AKT‐mTOR‐4EBP1 signaling pathway to enhance malignant phenotypes in ESCC.[19] Radiotherapy represents one of the primary treatment modalities for advanced ESCC. This evidence concerns the gene DHX9 and esophageal squamous cell carcinoma.